/ /

Vanessa Caceres
What to say when discussing MIGS with patients
When microinvasive glaucoma surgery is a potential treatment option, surgeons should present it as neutrally as possible.
Switching treatments for wet AMD poses numerous complexities
Switching treatments for wet AMD poses numerous complexities
Studies that focus on switching treatments for exudative age-related macular degeneration may represent more real-life scenarios. However, future prospective studies with predetermined switching criteria and follow-up are needed.
Animal model connects gene mutation and normal-tension glaucoma
Transgenic mice engineered to have extra copies of the TBK1 gene showed effects similar to those in human patients with normal-tension glaucoma, providing clues to pathophysiology and potential treatments.
5 pearls to manage white cataracts
Better management of white cataracts with these pearls can help avoid complications like the Argentinian flag sign.
Pseudoexfoliation syndrome not yet ready for genetic testing
Although the LOXL1 gene may increase the risk for pseudoexfoliation syndrome, currently available genetic testing does not effectively predict who will develop disease.
Levodopa for amblyopia explored as novel modality
A study of children with residual amblyopia did not find an advantage with the use of levodopa compared with a placebo group.
Metabolome-wide study finds link between androgen metabolism and dry eye
A metabolomics study found a link between dry eye disease and androgen metabolism in females.
Lutein, zeaxanthin assist in visual function both early, later in life
A diet that contains lutein and zeaxanthin—or supplementation with these two carotenoids—appears to benefit healthy vision throughout life.
Diabetes drug could reduce the risk of open-angle glaucoma
Use of metformin, a drug therapy for the treatment of diabetes, was found to be associated with reduced risk of adult-onset, open-angle glaucoma in a recent study.
Genotype-directed therapy may help patients with moderate AMD
Genotype-directed therapy may help patients with moderate AMD
Genotyping reveals that certain patients with moderate age-related macular degeneration may benefit more from the AREDS formulation than others.

Poll

View Results